Furodrag®

Solution for injection.

Diuretic.

Each mL of solution for injection contains:
Furosemide…………………50 mg
Excipients q.s.c…………….1 mL

Diuretic indicated in the treatment of acute pulmonary, mammary, gestational edema, congestive heart failure and ascites; It is also used as a support therapy in forced diuresis in cases of intoxication of various origins. Indicated in cases of renal failure with oliguria and in diagnostic procedures. In bleeding horses (epistaxis).

Horses and cattle.

Intravenous or intramuscular.

• Horses and cattle: 5 – 10 mL per animal (equivalent to 250-500 mg of Furosemide/animal), once or twice a day. Duration of treatment depends on the evaluation of the Veterinarian.

• Do not use in patients with anuria; acute glomerular nephritis and severe hepatic failure.
• Do not use in patients who are hypersensitive to furosemide.
• In patients with progressive renal disease whose azotemia and oliguria are increased during furosemide therapy, its administration should be discontinued.
• Do not administer to pregnant or lactating females.

• Furosemide may cause disturbances in fluid and electrolyte balance.
• Metabolic alkalosis can occur due to contraction of extracellular volume. In prolonged treatment it can cause hypokalemia or hyponatremia. Extracellular volume depletion and hyponatremia can lead to decreased blood pressure and tissue perfusion.
• Patients with kidney, heart or liver disease are at increased risk of developing adverse effects.

Furosemide may interact with: Theophylline (potentiates the effect), aminoglycosides or Cisplatin (potentiates ototoxicity and if the volume is high, nephrotoxicity), digitalis glycosides (the diuretic induces hypokalemia which may increase the risk of arrhythmias), Acetylsalicylic acid or other anticoagulants (increases the activity of the anticoagulant), neuromuscular blockers (alteration in the extent of muscle relaxation), corticosteroids (potentiates potassium loss), Insulin (alteration of insulin requirements associated with hyperglycemic effects), Lithium and Propanolol (increase in plasma levels), Probenecid (competition for diuretic secretion in the tubular lumen leading to decreased diuretic effect), non-steroidal anti-inflammatory drugs (decreased diuretic effect), and Thiazide (synergistic diuretic activity).

• Keep out of reach of children and pets.
• In the case of mammary gland oedema related to childbirth, treatment should not exceed 48 hours after childbirth. However, in each case, the doses may be adjusted according to the Veterinary Medical indication.
• Prolonged treatment with Furodrag® may cause a decrease in plasma potassium levels, which may require the administration of a supplement containing this element. Furosemide should be used with caution in patients with pre-existing electrolyte or water balance abnormalities (vomiting, diarrhea, etc.), impaired hepatic function (may trigger hepatic coma) or diabetes mellitus.
• High doses in cats and dogs may cause ototoxicity.

• Do not handle by pregnant women.
• Do not handle by persons hypersensitive to Furosemide.
• Wash hands immediately after administering the product.
• In case of contact with skin, eyes or mucous membranes, wash immediately with plenty of water. In case of irritation, seek medical attention and show the product leaflet. In case of accidental injection, seek medical attention immediately and show the product leaflet.

• Cattle: Meat and milk: 48 hours.
• Do not administer to horses whose meat is intended for human consumption.

Store at room temperature below 25°C. Do not refrigerate or freeze. Once opened, use within 28 days. Discard the unused product after that period of time. For export: Store at room temperature between 15 and 30 °C, protected from light.

Empty containers can be discarded as household waste, without any special precautions. Do not dispose of containers with product residues on the ground or in waterways. For expired or unused products, contact the manufacturing laboratory.

Sale by prescription to the Veterinary Doctor.

VETERINARY USE

Chile: Reg. SAG No. 1500
Rep. Dominican: Reg. No. 5598
Peru: Reg. SENASA F.14.01.I.0027

Ampoule bottle with 50 mL

Laboratorio Drag Pharma Chile Invetec S.A.
Lautaro N° 300. Quilicura. Santiago. Chile.